Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Safety and Efficacy of Istaroxime 1.0 and 1.5 µg/kg/min for Patients With Pre-Cardiogenic Shock.
Journal: Journal of cardiac failure
Published: March 23, 2023
Safety and efficacy of istaroxime in patients with acute heart failure-related pre-cardiogenic shock - a multicentre, randomized, double-blind, placebo-controlled, parallel group study (SEISMiC).
Journal: European journal of heart failure
Published: April 22, 2022
Efficacy and safety of an albiglutide liquid formulation compared with the lyophilized formulation: A 26-week randomized, double-blind, repeat-dose study in patients with type 2 diabetes mellitus.
Journal: Diabetes research and clinical practice
Published: November 08, 2018
A Randomized, Double-Blind, Single-Dose, Crossover Study to Demonstrate the Bioequivalence of 2 Formulations of Albiglutide in Healthy Adult Participants.
Journal: Clinical pharmacology in drug development
Published: February 08, 2018
Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial.
Journal: Journal of the American Heart Association
Published: October 26, 2017
Psychosocial stress and major cardiovascular events in patients with stable coronary heart disease.
Journal: Journal of internal medicine
Published: September 30, 2017
Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease.
Journal: Journal of the American College of Cardiology
Published: May 15, 2017
Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease.
Journal: International journal of cardiology
Published: April 19, 2017
Tooth loss is independently associated with poor outcomes in stable coronary heart disease.
Journal: European journal of preventive cardiology
Published: September 03, 2015
The pharmacokinetics and safety of darapladib in subjects with severe renal impairment.
Journal: British journal of clinical pharmacology
Published: September 23, 2014
Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A2 inhibitor, on arterial inflammation as assessed with 18F-fluorodeoxyglucose-positron emission tomography imaging.
Journal: Journal of the American College of Cardiology
Published: April 12, 2013
Showing 1-12 of 12
Last Updated: 09/26/2026